Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimizing Ponatinib Use (OPUS) in Chronic Phase CML Resistant to Imatinib
2015-001102-34Phase 2Terminated
- Sponsor
- GIMEMA
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ponatinib in chronic myelogenous leukemia (CML), sponsored by GIMEMA. Primary endpoint: Antileukemic activity of ponatinib as second-line therapy. Started Jun 2021; status: terminated.
02
Drugs
ponatinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2015-001102-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001102-34.